195 related articles for article (PubMed ID: 37796539)
21. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
22. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
23. Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.
Coll RP; Bright SJ; Martinus DKJ; Georgiou DK; Sawakuchi GO; Manning HC
Mol Imaging Biol; 2023 Dec; 25(6):991-1019. PubMed ID: 37845582
[TBL] [Abstract][Full Text] [Related]
24.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
25. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals.
Cai Z; Anderson CJ
J Labelled Comp Radiopharm; 2014 Apr; 57(4):224-30. PubMed ID: 24347474
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in theranostics and challenges for the future.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20170893. PubMed ID: 29565650
[TBL] [Abstract][Full Text] [Related]
27. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Lenzo NP; Meyrick D; Turner JH
Diagnostics (Basel); 2018 Feb; 8(1):. PubMed ID: 29439481
[TBL] [Abstract][Full Text] [Related]
28. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.
Petersen AL; Henriksen JR; Binderup T; Elema DR; Rasmussen PH; Hag AM; Kjær A; Andresen TL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):941-952. PubMed ID: 26646780
[TBL] [Abstract][Full Text] [Related]
29. Initial insights into the interaction of antibodies radiolabeled with Lutetium-177 and Actinium-225 with tumor microenvironment in experimental human and canine osteosarcoma.
Giri S; Allen KJH; Prabaharan CB; Ramirez JB; Fiore L; Uppalapati M; Dadachova E
Nucl Med Biol; 2024; 134-135():108917. PubMed ID: 38718557
[TBL] [Abstract][Full Text] [Related]
30. Subcellular Targeting of Theranostic Radionuclides.
Bavelaar BM; Lee BQ; Gill MR; Falzone N; Vallis KA
Front Pharmacol; 2018; 9():996. PubMed ID: 30233374
[TBL] [Abstract][Full Text] [Related]
31. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
32. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic radionuclides in nuclear medicine: current and future prospects.
Yeong CH; Cheng MH; Ng KH
J Zhejiang Univ Sci B; 2014 Oct; 15(10):845-63. PubMed ID: 25294374
[TBL] [Abstract][Full Text] [Related]
35. Nuclear Medicine and Cancer Theragnostics: Basic Concepts.
Zoi V; Giannakopoulou M; Alexiou GA; Bouziotis P; Thalasselis S; Tzakos AG; Fotopoulos A; Papadopoulos AN; Kyritsis AP; Sioka C
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835806
[TBL] [Abstract][Full Text] [Related]
36. Dual Radionuclide Theranostic Pretargeting.
Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
[TBL] [Abstract][Full Text] [Related]
37. Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of Concept.
Huclier-Markai S; Alliot C; Kerdjoudj R; Mougin-Degraef M; Chouin N; Haddad F
Cancer Biother Radiopharm; 2018 Oct; 33(8):316-329. PubMed ID: 30265573
[TBL] [Abstract][Full Text] [Related]
38. Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review.
Hussain M; Qaim SM; Spahn I; Aslam MN; Neumaier B
Front Chem; 2023; 11():1270351. PubMed ID: 37841203
[TBL] [Abstract][Full Text] [Related]
39. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
Shokeen M; Anderson CJ
Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
